Answers are grounded in this paper and cite their sources.
NEOSPHERE study, a randomized phase II trial that showed that adding pertuzumab to trastuzumab and docetaxel nearly doubled the rate of pCR (39.3% vs. 21.5%). Additional data from the TRYPHAENA study, as well as longer-term safety data from the phase III CLEOPATRA study of pertuzumab in metastatic breast cancer, were also submitted in support of the approval. (TRYPHAENA is a phase II study of neoadjuvant pertuzumab in earlystage breast cancer designed primarily to assess cardiac safety, but pCR was a secondary endpoint.)
No takes yet. Share an insight, caveat, or question.
J. Peres (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: